UNSPSC 51273931: Dextrose/tetracaine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.

UNSPSC 51273931 Dextrose/tetracaine is a Commodity code that captures state and local procurement of pharmaceutical products, though recent solicitations under this code reflect a broader scope of emergency-response and pharmaceutical-supply contracting than the code name alone suggests. State and local buyers are procuring naloxone and drug-deactivation systems for public health and community safety, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing alliances, and exploring direct-to-manufacturer pharmacy benefit programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing vehicles such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which coordinates procurement across state and local government facilities in multiple jurisdictions.

Recent activity spans Florida, Texas, and the Upper Midwest. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug-deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription fulfillment without pharmacy benefit managers or group purchasing organizations, framing a future formal solicitation. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (response due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson) to participating state and local facilities including Oregon, with awarded products effective July 1, 2026. Vendors must maintain cGMP certification, Drug Supply Chain Security Act compliance, and contractual relationships with at least two of three authorized wholesalers; evaluation weighting heavily favors price competitiveness (75 percent) over administrative and technical factors.